Jefferies Financial Group Inc. Makes New $6.94 Million Investment in DaVita Inc. $DVA

Jefferies Financial Group Inc. bought a new position in shares of DaVita Inc. (NYSE:DVA) during the 4th quarter, Holdings Channel reports. The institutional investor bought 61,051 shares of the company’s stock, valued at approximately $6,936,000.

Several other hedge funds have also recently bought and sold shares of the stock. Invesco Ltd. raised its holdings in DaVita by 2.0% during the 3rd quarter. Invesco Ltd. now owns 1,679,248 shares of the company’s stock worth $223,122,000 after buying an additional 32,358 shares during the period. Dimensional Fund Advisors LP grew its stake in shares of DaVita by 8.8% during the 3rd quarter. Dimensional Fund Advisors LP now owns 1,085,593 shares of the company’s stock worth $144,230,000 after acquiring an additional 88,061 shares in the last quarter. LSV Asset Management grew its stake in shares of DaVita by 1.1% during the 4th quarter. LSV Asset Management now owns 936,768 shares of the company’s stock worth $106,426,000 after acquiring an additional 9,739 shares in the last quarter. Arrowstreet Capital Limited Partnership grew its stake in shares of DaVita by 109.7% during the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 553,809 shares of the company’s stock worth $73,585,000 after acquiring an additional 289,725 shares in the last quarter. Finally, Neuberger Berman Group LLC grew its stake in shares of DaVita by 138.5% during the 3rd quarter. Neuberger Berman Group LLC now owns 463,250 shares of the company’s stock worth $61,502,000 after acquiring an additional 269,015 shares in the last quarter. 90.12% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several brokerages have recently weighed in on DVA. Deutsche Bank Aktiengesellschaft raised shares of DaVita from a “hold” rating to a “buy” rating and raised their price target for the stock from $126.00 to $220.00 in a research note on Wednesday, May 6th. UBS Group raised their price target on shares of DaVita from $190.00 to $235.00 and gave the stock a “buy” rating in a research note on Thursday, May 7th. Truist Financial raised their price target on shares of DaVita from $158.00 to $205.00 and gave the stock a “hold” rating in a research note on Friday, May 8th. Wall Street Zen raised shares of DaVita from a “hold” rating to a “buy” rating in a research note on Saturday, February 21st. Finally, TD Cowen raised their price target on shares of DaVita from $144.00 to $201.00 and gave the stock a “hold” rating in a research note on Monday, May 11th. One equities research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $199.17.

DaVita Stock Performance

Shares of DaVita stock opened at $198.39 on Tuesday. The firm has a 50-day moving average of $163.84 and a 200-day moving average of $138.82. The stock has a market cap of $12.74 billion, a PE ratio of 18.40, a PEG ratio of 0.65 and a beta of 0.84. DaVita Inc. has a 52-week low of $101.00 and a 52-week high of $202.69.

DaVita (NYSE:DVA) last announced its earnings results on Tuesday, May 5th. The company reported $2.87 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.33 by $0.54. The company had revenue of $3.42 billion during the quarter, compared to analysts’ expectations of $3.36 billion. DaVita had a net margin of 5.65% and a negative return on equity of 270.37%. DaVita’s quarterly revenue was up 6.0% on a year-over-year basis. During the same quarter in the previous year, the business posted $2.00 earnings per share. DaVita has set its FY 2026 guidance at 14.100-15.200 EPS. Equities research analysts predict that DaVita Inc. will post 15.07 earnings per share for the current fiscal year.

Insider Buying and Selling

In other DaVita news, CFO Joel Ackerman sold 51,471 shares of DaVita stock in a transaction dated Thursday, May 7th. The stock was sold at an average price of $192.10, for a total value of $9,887,579.10. Following the transaction, the chief financial officer owned 132,434 shares in the company, valued at $25,440,571.40. The trade was a 27.99% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 1.50% of the stock is currently owned by company insiders.

DaVita Company Profile

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.